
Repros Therapeutics says positive results from Phase II trial of uterine fibroids drug; shares jump
pharmafile | April 15, 2016 | News story | Medical Communications, Research and Development |ย ย Repros Therapeutics, Shares, US FDA, drug trial, uterine fibroidsย
Shares in Repros Therapeutics (Nasdaq: RPRX) surged to close over 18% Thursday after the company announced positive mid-stage trial results for its drug candidate to treat uterine fibroids.
The company said the trial showed its Proellex significantly reduced excessive menstrual bleeding in women with uterine fibroids. The company will now work with the US Food and Drug Administration (FDA) to plan a Phase III trial.
Repros Therapeutics is engaged in the development of new drugs to treat hormonal and reproductive system disorders.
Shares in the company closed up 18.7% at $2.67 Thursday on the Nasadq.
Anjali Shukla
Related Content

Uterine fibroids and the cost of silence
By Tina Backhouse Stigma and shame Every month, most women on the planet have a …

Pfizer and Myovantโs menstrual blood loss treatment reports 78% effectiveness
Pfizer and Myovant Scienceโs relugolix treatment to reduce menstrual blood loss in women with uterine …

Lawsuit against FDA claims Bernie Sanders played role in approval of rival drug
Catalyst Pharmaceutical is attempting to show in court that pressure from US Senator Bernie Sanders …






